Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

Publication: Amylyx Pharmaceuticals, Inc. | Publication Date: April 13, 2023

Authors: Amylyx Pharmaceuticals, Inc.

Significance

Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome

Read the entire research article here